SCHEMBL7134591

SCHEMBL7134591

NC(=O)c1ccc(Cc2ccc(C(N)=O)cc2)cc1

nearest known ligand 0.83

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLA2G10 O15496 1/20 0.83
PLA2G2A P14555 1/20 0.83
CYP17A1 P05093 1/20 0.68
KMT2A Q03164 2/20 0.58
PARP10 Q53GL7 8/20 0.57
PARP1 P09874 3/20 0.52
TSHR P16473 2/20 0.52
POLB P06746 1/20 0.52
CYP3A4 P08684 1/20 0.52
MAPT P10636 1/20 0.52
CYP2C19 P33261 1/20 0.52
RECQL P46063 1/20 0.52
BLM P54132 1/20 0.52
PMP22 Q01453 1/20 0.52
HSD17B10 Q99714 1/20 0.52
TDP1 Q9NUW8 1/20 0.52
L3MBTL1 Q9Y468 1/20 0.52
PARP4 Q9UKK3 2/20 0.52
ALDH1A1 P00352 1/20 0.52
PARP15 Q460N3 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1719129 0.91 PLA2G2A (1.00) PLA2G10PLA2G2ACYP17A1KMT2APARP10
SCHEMBL12663746 0.89 PLA2G10 (0.68) PLA2G10PLA2G2ACYP17A1KMT2APARP10
SCHEMBL18455085 0.87 PLA2G10 (0.66) PLA2G10PLA2G2ACYP17A1KMT2APARP10
SCHEMBL23905177 0.87 CYP17A1 (0.89) PLA2G10PLA2G2ACYP17A1KMT2APARP10
SCHEMBL28396819 0.87 PLA2G2A (0.92) PLA2G10PLA2G2ACYP17A1KMT2APARP10
SCHEMBL6804938 0.84 PARP10 (0.64) PLA2G10PLA2G2ACYP17A1PARP10PARP15
SCHEMBL8213818 0.84 PARP10 (0.78) PLA2G10PLA2G2ACYP17A1KMT2APARP10
SCHEMBL22721356 0.84 MAOB (0.67) PLA2G10PLA2G2ACYP17A1ALDH1A1MAOB
Terephthalamide SCHEMBL23774 0.83 PARP1 (0.71) PLA2G10PLA2G2AKMT2APARP10PARP1
SCHEMBL22284875 0.82 CYP17A1 (1.00) PLA2G10PLA2G2ACYP17A1TSHRCYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3125033-B1 LIQUID CRYSTAL DISPLAY DEVICE JNC CORP (JP) 2021-06-02 EP disclosed
EP-3179303-B1 LIQUID CRYSTAL DISPLAY ELEMENT JNC CORP (JP) 2020-04-01 EP disclosed
EP-3133136-B1 LIQUID CRYSTAL DISPLAY DEVICE JNC CORP (JP) 2019-08-07 EP disclosed
EP-3163368-B1 LIQUID CRYSTAL DISPLAY ELEMENT JNC CORP (JP) 2019-06-26 EP disclosed
EP-3163368-A1 LIQUID CRYSTAL DISPLAY ELEMENT JNC Corporation (JP) 2017-05-03 EP disclosed
EP-3133136-A1 LIQUID CRYSTAL DISPLAY ELEMENT JNC Corporation (JP) 2017-02-22 EP disclosed
EP-3125033-A1 LIQUID CRYSTAL DISPLAY ELEMENT JNC Corporation (JP) 2017-02-01 EP disclosed
WO-2003051347-A1 USE OF UROKINASE RECEPTOR ANTAGONISTS TO MODULATE ISCHEMIAREPERFUSION INJURY VLAAMS INTERUNIVERSITAIR INSTITUUT VOOR BIOTECHNOLOGIE VZW (BE) 2003-06-26 WO disclosed
US-5792840-A SUBSTITUTED GLUCOPYRANOSYL PHOSPHATES SANKYO COMPANY, LIMITED (JP) 1998-08-11 US disclosed
EP-0437016-B1 Lipid A analogues having immunoactivating and anti-tumour activity SANKYO CO (JP) 1996-05-01 EP disclosed
EP-0437016-A2 Lipid A analogues having immunoactivating and anti-tumour activity Sankyo Company Limited (JP) 1991-07-17 EP disclosed
US-4369311-A Method of preparation of cyclic nitrile sulfites THE DOW CHEMICAL COMPANY (US) 1983-01-18 US disclosed